Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neuroblastoma 9Prostatic Neoplasms 3Precancerous Conditions 3Glioma 3Astrocytoma 3Adenomatous Polyposis Coli 3Skin Neoplasms 2Sarcoma, Ewing 2Osteosarcoma 2Neuroectodermal Tumors, Primitive 2Medulloblastoma 2Glioblastoma 2Colorectal Neoplasms 2Carcinoma, Basal Cell 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Typical Teratoid Rhabdoid Tumor 1Stomach Neoplasms 1Rhabdoid Tumor 1Osteosarcoma Recurrent 1Oligodendroglioma 1Non-melanoma Skin Cancer 1Neoplasms 1Melanoma 1Lymphoma, Follicular 1Lung Neoplasms 1Keratosis, Actinic 1Gastritis, Atrophic 1Esophageal Neoplasms 1

Interventions

Cisplatin 161Fluorouracil 135Paclitaxel 127Radiotherapy 125Oxaliplatin 88Carboplatin 72Docetaxel 71Irinotecan 60pembrolizumab 57Leucovorin 57Capecitabine 57Radiation 48Esophagectomy 44Surgical Procedures, Operative 42Drug Therapy 38Neoadjuvant Therapy 28Cetuximab 25Nivolumab 24Bevacizumab 21camrelizumab 20Trastuzumab 20S 1 (combination) 19Chemoradiotherapy 19Magnetic Resonance Spectroscopy 18Epirubicin 16Albumin-Bound Paclitaxel 16Blood Specimen Collection 15tislelizumab 14Taxes 14Radiotherapy, Intensity-Modulated 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Neoplasms × Eflornithine × Clear all
NCT00003076 2012-12-19

Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus

University of Michigan Rogel Cancer Center

Phase 2 Completed
152 enrolled
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡